Cargando…
Das Herz bei viralen Infektionen
Between 10 and 20% of patients with histologically proven inflammatory disease of the heart muscle develop a chronic disorder after acute myocarditis which results in dilated cardiomyopathy with increasing cardiac insufficiency. Viral infections are a frequent cause of inflammatory heart muscle dise...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096081/ https://www.ncbi.nlm.nih.gov/pubmed/20532860 http://dx.doi.org/10.1007/s00108-009-2559-8 |
_version_ | 1783510747679031296 |
---|---|
author | Pankuweit, S. Maisch, B. |
author_facet | Pankuweit, S. Maisch, B. |
author_sort | Pankuweit, S. |
collection | PubMed |
description | Between 10 and 20% of patients with histologically proven inflammatory disease of the heart muscle develop a chronic disorder after acute myocarditis which results in dilated cardiomyopathy with increasing cardiac insufficiency. Viral infections are a frequent cause of inflammatory heart muscle diseases and thus also responsible for myocardial damage in the initial phase. In the past, evidence for enterovirus, adenovirus, and cytomegalovirus was in the focus of attention. In the meantime, “new” cardiotropic pathogens such as parvovirus B19, Epstein-Barr virus, and human herpesvirus 6 have been detected in patients with dilated cardiomyopathy with and without inflammation. Their persistence in the myocardium correlates with a decline in pumping capability within 6 months. While the virus is still being eliminated, the second phase of the disease begins, which is characterized by autoimmune phenomena and often a cardiac inflammatory response which likewise correlates with a worsening prognosis. The transition to the third and final phase with development of dilated cardiomyopathy occurs gradually and can take years. The goal of every diagnostic and therapeutic intervention must be to eradicate the virus and eliminate the inflammatory response to prevent the disease from progressing to terminal cardiac insufficiency. |
format | Online Article Text |
id | pubmed-7096081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-70960812020-03-26 Das Herz bei viralen Infektionen Pankuweit, S. Maisch, B. Internist (Berl) Schwerpunkt Between 10 and 20% of patients with histologically proven inflammatory disease of the heart muscle develop a chronic disorder after acute myocarditis which results in dilated cardiomyopathy with increasing cardiac insufficiency. Viral infections are a frequent cause of inflammatory heart muscle diseases and thus also responsible for myocardial damage in the initial phase. In the past, evidence for enterovirus, adenovirus, and cytomegalovirus was in the focus of attention. In the meantime, “new” cardiotropic pathogens such as parvovirus B19, Epstein-Barr virus, and human herpesvirus 6 have been detected in patients with dilated cardiomyopathy with and without inflammation. Their persistence in the myocardium correlates with a decline in pumping capability within 6 months. While the virus is still being eliminated, the second phase of the disease begins, which is characterized by autoimmune phenomena and often a cardiac inflammatory response which likewise correlates with a worsening prognosis. The transition to the third and final phase with development of dilated cardiomyopathy occurs gradually and can take years. The goal of every diagnostic and therapeutic intervention must be to eradicate the virus and eliminate the inflammatory response to prevent the disease from progressing to terminal cardiac insufficiency. Springer-Verlag 2010-06-09 2010 /pmc/articles/PMC7096081/ /pubmed/20532860 http://dx.doi.org/10.1007/s00108-009-2559-8 Text en © Springer-Verlag 2010 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Schwerpunkt Pankuweit, S. Maisch, B. Das Herz bei viralen Infektionen |
title | Das Herz bei viralen Infektionen |
title_full | Das Herz bei viralen Infektionen |
title_fullStr | Das Herz bei viralen Infektionen |
title_full_unstemmed | Das Herz bei viralen Infektionen |
title_short | Das Herz bei viralen Infektionen |
title_sort | das herz bei viralen infektionen |
topic | Schwerpunkt |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096081/ https://www.ncbi.nlm.nih.gov/pubmed/20532860 http://dx.doi.org/10.1007/s00108-009-2559-8 |
work_keys_str_mv | AT pankuweits dasherzbeiviraleninfektionen AT maischb dasherzbeiviraleninfektionen |